The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and ...

BioAdaptives detailed the strategy behind its Xcellara platform, combining stem cell mobilization with tissue-targeting ...

BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform ...

Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the ...

A healthy bone marrow (BM) produces nearly all types of cells in our blood. Many blood disorders occur when hematopoietic ...

PR Newswire TEL AVIV, Israel and OSLO, Norway, July 20, 2026 TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinica ...

A healthy bone marrow (BM) produces nearly all types of cells in our blood. Many blood disorders occur when hematopoietic ...

In the phase 3 SUBITO trial, researchers aimed to compare outcomes with intensified alkylating chemotherapy to those with an HRD-targeting regimen.

Detailed price information for Biolinerx Ltd ADR (BLRX-Q) from The Globe and Mail including charting and trades.

By freezing your own healthy blood stem cells in your 20s, thawing them and undergoing a stem cell transplant in your 40s or ...

A team led by bioengineers at the University of California San Diego has developed a genome-scale reference map that details ...

Texas A&M researchers found a way to make stem cells produce double the normal number of mitochondria using nanoflower particles. These energized stem cells then transfer their surplus “power packs” ...